Irinotecan HCl Trihydrate

For research use only.

Catalog No.S2217 Synonyms: CPT-11 HCl Trihydrate

38 publications

Irinotecan HCl Trihydrate Chemical Structure

Molecular Weight(MW): 677.18

Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 190 In stock
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Irinotecan HCl Trihydrate has been cited by 38 publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.
Features Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.
Targets
Topo I [1]
In vitro

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. [1] The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. [2] Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. [3] Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse bone marrow cell M3vJT2N6fG:2b4jpZ4l1gSCjc4PhfS=> NVHJNVJ4S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4Uh[m:wZTDtZZJzd3diY3XscEBjgSCFRmWtS20h[XO|YYmuJGlEPTB;MD6wNFEh|ryP MYKyNVM1OTZ5NB?=
PC3 cells M4XrT2N6fG:2b4jpZ4l1gSCjc4PhfS=> MXS3NkBp MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LjDJR|UxRTBwMESg{txO NIfVb2czOTN2MU[3OC=>
A375 cells M4nLZmN6fG:2b4jpZ4l1gSCjc4PhfS=> M3PuNFczKGh? MlfpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6wOEDPxE1? M1nsO|IyOzRzNke0
LNCAP cells M4\SPGN6fG:2b4jpZ4l1gSCjc4PhfS=> MX63NkBp M1G5NmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlA6KM7:TR?= M1TZNlIyOzRzNke0
MESSA cells NYTVXZpZS3m2b4TvfIlkcXS7IHHzd4F6 MWm3NkBp NX;3TpczS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVU1GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NiCLQ{WwQVAvODFizszN NVPYWFdqOjF|NEG2O|Q>
H460 cells NXG2O41ZS3m2b4TvfIlkcXS7IHHzd4F6 MmD3O|IhcA>? NFXjdHpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlAyPSEQvF2= MkOzNlE{PDF4N{S=
MES-SA/Dx5 cells MWXDfZRwfG:6aXPpeJkh[XO|YYm= NG\TOHY4OiCq NX7N[IM4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlAzOiEQvF2= Mnu3NlE{PDF4N{S=
H69 cells M3\IWGN6fG:2b4jpZ4l1gSCjc4PhfS=> MUm3NkBp MmTsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFY6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeT6gTWM2OD1yLkCyNkDPxE1? M3zB[lIyOzRzNke0
IGROV1 cells NV[1OI5sS3m2b4TvfIlkcXS7IHHzd4F6 MUK3NkBp MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJS3JQXjFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MkBKSzVyPUCuNFMh|ryP M13Kc|IyOzRzNke0
SK-MEL-2 cells M{ewWWN6fG:2b4jpZ4l1gSCjc4PhfS=> MlH3O|IhcA>? MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1OTUxvMjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZkvKEmFNUC9NE4yKM7:TR?= NE\EU2EzOTN2MU[3OC=>
MALME-3M cells M3Ltb2N6fG:2b4jpZ4l1gSCjc4PhfS=> M4K3UlczKGh? NE\JSHlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOSUyPRT2zUUBk\WyuczDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XlwIFnDOVA:OC5{IN88US=> MnyyNlE{PDF4N{S=
DU145 cells NHrJbJVEgXSxdH;4bYNqfHliYYPzZZk> MYK3NkBp M1nQfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlIh|ryP MV6yNVM1OTZ5NB?=
HT-29 cells NYr0Oo15S3m2b4TvfIlkcXS7IHHzd4F6 NUT3O25jPzJiaB?= M3faN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlIzKM7:TR?= NGDKNlAzOTN2MU[3OC=>
H69AR cells NFO1W2ZEgXSxdH;4bYNqfHliYYPzZZk> NGnYdIM4OiCq MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOllCWiClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfU4hUUN3ME2wMlI2KM7:TR?= MWSyNVM1OTZ5NB?=
MCF7 cells NIDsWYtEgXSxdH;4bYNqfHliYYPzZZk> M1PWbFI1KGh? MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhVVSVIHHzd4F6NiCLQ{WwQVAvPSEQvF2= M{K0PFI3QDRzMU[4
HCT116 MlTISpVv[3Srb36gZZN{[Xl? MWPDc41xd3WwZDD3ZZMhfGW|dHXkJIlvKH[rdILvJIZweiCleYTveI95cWOrdImgZYdicW6|dDDIR3QyOTZuIHj1cYFvKGOxbH;uJINidmOncjDj[YxteyBqdHH4c4wuemW|aYP0ZY51MSCjdDDhJIRzfWdiY3;uZ4VvfHKjdHnvckBxem:mdXPpcochPTBnIHnubIljcXSrb36gc4Yh[2:ub375JIZwem2jdHnvck4hUUN3ME2wMlU1KM7:TR?= MnfuNVE6PjV|NkK=
RPMI8402 MlPaR5l1d3SxeHnjbZR6KGG|c3H5 MmrtOEBl[Xm| NF;0W4JEgXSxdH;4bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDsfY1xcG:kbHHzeEB1fW2xcjDj[YxtKGyrbnWgVnBOUTh2MEKgZYZ1\XJiNDDkZZl{KG:oIITy[YF1dWWwdD6gTWM2OD1yLkW3JO69VQ>? MnryNVI4PDd5OUi=
KB3-1 cells MV\DfZRwfG:6aXPpeJkh[XO|YYm= NV\vVmZIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0J|LUGgZ4VtdHNiYomgUXRVKG2ndHjv[E4hUUN3ME2wMlY5KM7:TR?= MnrmNVg4PzF7M{C=
PC3 cells NFnNTVBRem:uaX\ldoF1cW:wIHHzd4F6 MYi3NkBp NHXhZW9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyudXzhdkBFVkFiY3;ueIVvfCCjZoTldkA4OiCqcoOgZpkhS3mTVVHOWEBPTiCobIXvdoV{[2WwY3WgZZN{[XlwIFnDOVA:OC56IN88US=> MmjyNlY4OzF|MEC=
A549 cells NVXUPY5VS3m2b4TvfIlkcXS7IHHzd4F6 Ml\6NlQhcA>? Mn\NR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WUzDhd5NigS5iSVO1NF0xNjhizszN MYqyOlg1OTF4OB?=
MCF7 cells NEXC[mxRem:uaX\ldoF1cW:wIHHzd4F6 NUXkNYIzQTZiaB?= Mn;GRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJINmdGy3bHHyJGRPSSClb370[Y51KGGodHXyJFk3KGi{czDifUBEgVGXQV7UJG5HKG[udX;y[ZNk\W6lZTDhd5NigS5iSVO1NF0xNjlizszN MYWyOlc{OTNyMB?=
HepG2 cells MWfDfZRwfG:6aXPpeJkh[XO|YYm= Ml;YNlQhcA>? NIToWmxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IF3UV{Bie3OjeT6gTWM2OD1yLkmg{txO NWjLUHJ1OjZ6NEGxOlg>
MDA-MB-435 cells MWHDfZRwfG:6aXPpeJkh[XO|YYm= MlXUO|IhcA>? MoHhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LjDJR|UxRTFwMUSg{txO Mn;oNlA{PzFzOEO=
LS174T cells MnrYR5l1d3SxeHnjbZR6KGG|c3H5 MYi5OkBp MoHIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHMyPzSWIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZkvKEmFNUC9NU4yPiEQvF2= NGizOY4yQDVzM{m3Oi=>
T84 cells NFzKeWVRem:uaX\ldoF1cW:wIHHzd4F6 MkLOPVYhcA>? M4jpfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVEi0JINmdGy|IHHzd4V{e2WmIHHzJINmdGy3bHHyJGRPSSClb370[Y51KGGodHXyJFk3KGi{czDifUBEgVGXQV7UJG5HKG[udX;y[ZNk\W6lZTDhd5NigS5iSVO1NF0yNjJizszN M4[yUlI3PzNzM{Cw
SW480 cells MVnDfZRwfG:6aXPpeJkh[XO|YYm= MoHFNlQhcA>? NHrJdGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzR6MDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IF3UV{Bie3OjeT6gTWM2OD1zLkSg{txO NYXnV|FNOjZ6NEGxOlg>
K562 cells M2WzSnBzd2yrZnXyZZRqd25iYYPzZZk> NGnCUmc4OiCq NFrLdXNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiN{KgbJJ{NiCLQ{WwQVEvQSEQvF2= MnjONlU1OjBzN{W=
HT-29 cells NVjWXGhDWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mli3O|IhcA>? MlLGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyudXzhdkBFVkFiY3;ueIVvfCCjZoTldkA4OiCqcoOgZpkhS3mTVVHOWEBPTiCobIXvdoV{[2WwY3WgZZN{[XlwIFnDOVA:OS57IN88US=> NIi1e4szPjd|MUOwNC=>
HCT116 cells M3GwUXBzd2yrZnXyZZRqd25iYYPzZZk> NYH3[2x[OjRvN{KgbC=> M2rsXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEK0JJRwKDd{IHjyd{BjgSCVUlKgZZN{[XlwIFnDOVA:OiEQvF2= MWSyOlU6PTh5NR?=
Hep3B cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 Mn\5O|IhcA>? M{GwTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwN2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGjUWEBie3OjeT6gTWM2OD12LkezJO69VQ>? M4f1[lE6Pzl4OUW2
Hep3B cells M17wPWdzd3e2aDDpcohq[mm2b36gZZN{[Xl? M{jqT|czKGh? MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[ZA{SiClZXzsd{Bi\nSncjC3NkBpenNiYomgXHRVKGG|c3H5MkBKSzVyPUSuO|Mh|ryP NELGOFAzOjB5OUK1OC=>
LoVo cells MkW2R5l1d3SxeHnjbZR6KGG|c3H5 Mo\hO|IhcA>? NHvGWFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNd1[xIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZkvKEmFNUC9OE46QSEQvF2= MXWyNFM4OTF6Mx?=
KBH5.0 cells MUPDfZRwfG:6aXPpeJkh[XO|YYm= NXLPfnJwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0KKNT6wJINmdGy|IHL5JG1VXCCvZYToc4QvKEmFNUC9O{41KM7:TR?= MnnnNVg4PzF7M{C=
H3347 cells NIjCfIZEgXSxdH;4bYNqfHliYYPzZZk> M1GyWFczKGh? M3;PemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg{OzR5IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIhSmy3ZTDhd5NigS5iSVO1NF04NjV|IN88US=> MkjzNlQ2QDN|NUW=
HCT15 cells M1vF[nBzd2yrZnXyZZRqd25iYYPzZZk> NXL3eHlwOjRvN{KgbC=> NVrJR4psSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjCyOEB1dyB5MjDodpMh[nliU2LCJIF{e2G7LjDJR|UxRThwNTFOwG0> NX3qcohiOjZ3OUW4O|U>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AMPK / p-AMPK / mTOR / p-mTOR / p70S6K / p-p70S6K; 

PubMed: 25973791     


Western blot showing the protein levels of AMPK, p-AMPK, mTOR, p-mTOR, p70S6K, and p-p70S6K in LoVo and LoVo-R8 with or without irinotecan. 

NFκB p65 / phospho-NFκB p65 / NFκB p50 / IκBα / p27Kip1; 

PubMed: 22206574     


For Western blot analysis (B), cytoplasmic proteins were analyzed using antibodies against NFκB p65 and p50, phospho-NFκB p65, IκBα and p27Kip1. In the presence of irinotecan, there was a loss of cytoplasmic NF-κBp65, but in the presence of sorafenib, this loss was greatly reduced, corresponding to a decrease in phosphorylation of NF-κBp65. In addition, compared to treatment with sorafenib or irinotecan alone, there was increased expression of IκBα following treatment with sorafenib and irinotecan. Lastly, following treatment with irinotecan and sorafenib irinotecan combination, there was decreased expression of p27Kip1 compared to sorafenib treatment alone.

TopI / pAKT / pMEK / pERK / p-p38 MAPK / pJNK2; 

PubMed: 29237470     


a Gimatecan significantly inhibited the expression of TopI, pAKT, pMEK, and pERK, and activated the expression of p-p38 MAPK and pJNK2 in SNU-1 cells. b Gimatecan significantly inhibited the expression of pAKT and pERK in NCI-N87 cells. Cells were starved in serum-free medium overnight, exposed to gimatecan or irinotecan for 48 h and harvested at 70–80% confluence. Total protein of SNU-1 and NCI-N87 was extracted and the expression of TopI, pAKT, pMEK, pERK, p-p38 MAPK and pJNK2 were assessed by western-blotting 

25973791 22206574 29237470
Immunofluorescence
NFκB; 

PubMed: 22206574     


BT12 cells were incubated with sorafenib or vehicle for 30 minutes followed by treatment with irinotecan for an additional 2 hours. For indirect immunofluorescence (A), cells were fixed and stained with antibodies to NF-κB followed by fluorescent labeled secondary antibodies. Concurrent DAPI stain was used to localize the nuclei (lower panel). Slides were visualized using a fluorescent microscope and random fields were photographed. The cytoplasmic staining seen in untreated and sorafenib treated cells was significantly reduced following treatment with irinotecan. However, the addition of sorafenib enabled the cells to maintain cytoplasmic staining in the presence of irinotecan. 

22206574
Growth inhibition assay
Cell viability; 

PubMed: 25973791     


The sensitivity of eight colon cancer cell lines to irinotecan was measured using the CCK-8 assay. For the CCK-8 assay, cells were exposed to irinotecan at given concentrations for 72 h before measurement. The cell viability was presented as the percentage relative to untreated cells.

25973791
In vivo In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. [5] A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. [6]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: LoVo and HT-29 cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 48 hours
  • Method:

    Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Female nude mice with COLO 320 and WiDr xenografts.
  • Dosages: 20 mg/kg
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (147.67 mM)
Water 1 mg/mL (1.47 mM)
Ethanol '7 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+saline
For best results, use promptly after mixing.
20mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 677.18
Formula

C33H38N4O6.HCl.3H2O

CAS No. 136572-09-3
Storage powder
in solvent
Synonyms CPT-11 HCl Trihydrate
Smiles O.O.O.Cl.CCC1=C2CN3C(=O)C4=C(C=C3C2=NC5=CC=C(OC(=O)N6CCC(CC6)N7CCCCC7)C=C15)C(O)(CC)C(=O)OC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04238819 Not yet recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company July 31 2020 Phase 1
NCT04158349 Not yet recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah May 2020 Phase 1
NCT04164979 Recruiting Drug: Cabozantinib|Drug: Pembrolizumab Gastric Adenocarcinoma|GastroEsophageal Cancer University of California Irvine|Exelixis February 4 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Irinotecan HCl Trihydrate | Irinotecan HCl Trihydrate supplier | purchase Irinotecan HCl Trihydrate | Irinotecan HCl Trihydrate cost | Irinotecan HCl Trihydrate manufacturer | order Irinotecan HCl Trihydrate | Irinotecan HCl Trihydrate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID